Table 2:
Differences in medical expenditures for treating disease conditions between real and hypothetical non-WHI scenarios over a 13-year cumulative period (2003–2015): Women of All Ages between 50–79
| Disease conditions stratified by age groups (years) | Counts of disease attributable to ET (rates in ET group minus rate in placebo) (95%LCL,95%UCL) | aCumulative medical expenditure differences between real and hypothetical non-WHI scenarios ($millions) | |
|---|---|---|---|
| Annual (95%LCL,95%UCL) | 13-Years (95%LCL,95%UCL) | ||
| Women with Hysterectomy | |||
| Breast Cancer | −13820 (−5206, −22435) | −83(−31, −135) | −1079 (−403, −1755) |
| Coronary heart disease (CHD) | 9214 (3470, 14957) | 125 (47, 204) | 1625 (611, 2652) |
| Stroke | −32248 (−12146, −52349) | −142 (−54, −231) | −1846 (−702, −3003) |
| Pulmonary Embolism | 4607 (1735, 7478) | 38 (14, 62) | 494 (182, 806) |
| Colorectal Cancer | −9214 (−3470, −14957) | −146 (−55, −237) | −1898 (−715, −3081) |
| Hip Fracture | 9214 (3470, 14957) | 39 (15, 64) | 507 (195, 832) |
| Global Index | 23034 (8676, 37392) | 133 (50, 215) | 1729 (650, 2795) |
| All Women | |||
| Breast Cancer | −18314 (−2767, −34609) | −110 (−17, −209) | −1430 (−221, −2717) |
| Coronary heart disease (CHD) | 12209 (1845, 23073) | 166 (25, 314) | 2158 (325, 4082) |
| Stroke | −42732 (−6457, −80755) | −189 (−29, −357) | −2457 (−377, −4641) |
| Pulmonary Embolism | 6104 (922, 11536) | 51 (8, 96) | 663 (104, 1248) |
| Colorectal Cancer | −12209 (−1845, −23073) | −193 (−29, −365) | −2509 (−377, −4745) |
| Hip Fracture | 12209 (1845, 23073) | 52 (8, 98) | 676 (104, 1274) |
| Global Index | 30523 (4612, 57682) | 176 (27, 332) | 2288 (351, 4316) |
The unit expenditure per disease based on MEPS (2003–2015) data are: $6027.91, breast cancer; $4415.65, CHD; $5761.94, stroke; $4257.01, PE; $13618.06, colorectal cancer; $15812.83, hip fracture; $8315.01, global index. The 95% CIs are obtained from repeating the analysis using the 95% CIs of the non-WHI estrogen usage trend.
The annual expenditures accrued during each year of the observation period, 2003–2015, were summed up to generate 13-year cumulative expenditures associated with treating chronic condition. A positive difference in the medical expenditures corresponds to excess cost of treatment of excess diseases. Conversely, negative differences correspond to monetary savings in medical expenditures for diseases averted.